BioSpace News Archive

MediSpend announced that Karyopharm Therapeutics (NASDAQ: KPTI) selected MediSpend Transparency Solution to comply with state and federal transparency reporting regulations. MediSpend Transparency Solution is a SaaS-based solution that collects, remediates, validates, analyzes and reports transfers of value to comply with state,

Cutaneous Lymphoma Foundation and Lymphoma Research Foundation are Grantees from First Round of Funding Kyowa Kirin Issues a Renewed Call for Submissions, with the Grant Program Extended to 2021

ExtriCARE USA, a national medical device company specializing in the distribution of negative pressure wound therapy (NPWT), officially announces its company launch and new user-centric website.

Minnetronix Medical, which partners with companies throughout the world to design, develop and manufacture medical device technology, today announced that it has been awarded a National Institutes of Health (NIH) granti for continued study of its proprietary Neurapheresis™ Cerebrospinal Fluid Treatment Platform

DiFusion Inc, unveiled groundbreaking Osteoimmunology data at the North American Spine Society 2020 Annual Meeting demonstrating the superiority of the new biomaterial ZFUZE over Nano-Surfaced Titanium and conventional PEEK materials

GigaGen Inc. , a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today publication of a peer-reviewed article titled, “Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR,” in the peer-reviewed journal mAbs. The publication is available online here. GigaGen’s newly published data detai

InstaShield, maker of the original ball-cap face shield, has been named one of the winners of the 19th annual Chicago Innovation Awards.

Palladio Biosciences, Inc. (Palladio), a privately-owned, clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney, announced today the results of a study that investigated the use of lixivaptan in a patient with autosomal dominant polycystic kidney disease (ADPKD) who could not tolerate a different vasopressin V2 receptor antagonist, tolvaptan. The presentation will be made as an ePos

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its third quarter 2020 financial results before the market opens on Thursday, October 29, 2020. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the result

The Ad Council today announced new research findings regarding the current state of loneliness around the world.1